Search results for ""
| Status | Drug name | NICE TAs | Comments | Subchapter |
|---|---|---|---|---|
 |
Flexitol® 25% urea heak balm | Specialist recommendation |
13.2 | |
 |
Flourescein sodium 10% injection (10 x 5ml amps) | 11.8 | ||
 |
Flucinolone acetonide 0.025% ointment | 13.4 | ||
|
Flucitasone and salmeterol | 3.2 | ||
|
Flucitasone and salmeterol (Seretide®) | For existing patients, for paediatric use only (i.e. up to 18 years of age) - APC listing of current formulary brands |
3.2 | |
|
Flucitasone furoate (Avamys) | Approved for use in children and adults. Previous APC decision reviewed in December 2015. |
12.2 | |
|
Flucitasone inhaler (Flixotide) evohaler 125 / Fluticasone accuhaler 250 | For paediatric use only |
3.2 | |
|
Flucitasone inhaler (Flixotide) evohaler 50 / Fluticasone accuhaler 50, 100 | For paediatric use only |
3.2 | |
|
Flucitasone propionate and azelastine (Dymista®) | Third line option for adults and children over 12 with moderate to severe allergic rhinitis who have failed ot respond to a steroid nasal spray with the addition of an oral antihistamine. Follow APC treatment algorithm. |
12.2 | |
|
Fludarabine injection | 8.1 |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- Next page
- Last page
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
